JP2018525358A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018525358A5 JP2018525358A5 JP2018502669A JP2018502669A JP2018525358A5 JP 2018525358 A5 JP2018525358 A5 JP 2018525358A5 JP 2018502669 A JP2018502669 A JP 2018502669A JP 2018502669 A JP2018502669 A JP 2018502669A JP 2018525358 A5 JP2018525358 A5 JP 2018525358A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- composition according
- cell lymphoma
- apilimod
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 51
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 239000013543 active substance Substances 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 229960003301 nivolumab Drugs 0.000 claims 6
- 229950002889 apilimod Drugs 0.000 claims 5
- HSKAZIJJKRAJAV-KOEQRZSOSA-N n-[(e)-(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine Chemical compound CC1=CC=CC(\C=N\NC=2N=C(OCCC=3N=CC=CC=3)N=C(C=2)N2CCOCC2)=C1 HSKAZIJJKRAJAV-KOEQRZSOSA-N 0.000 claims 5
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 5
- 229960004528 vincristine Drugs 0.000 claims 5
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 5
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 4
- 208000009011 Cytochrome P-450 CYP3A Inhibitors Diseases 0.000 claims 4
- 229960004679 doxorubicin Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 4
- 229960005205 prednisolone Drugs 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 3
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims 3
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229960001507 ibrutinib Drugs 0.000 claims 3
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 229940099039 velcade Drugs 0.000 claims 3
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 2
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 claims 2
- ZCIGNRJZKPOIKD-CQXVEOKZSA-N cobicistat Chemical compound S1C(C(C)C)=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SC=NC=2)CC=2C=CC=CC=2)=C1 ZCIGNRJZKPOIKD-CQXVEOKZSA-N 0.000 claims 2
- 229960002402 cobicistat Drugs 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 229960003413 dolasetron Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229960005167 everolimus Drugs 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 2
- 229960003727 granisetron Drugs 0.000 claims 2
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- GAJWNIKZLYZYSY-OKUPSQOASA-N methanesulfonic acid;n-[(e)-(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CC1=CC=CC(\C=N\NC=2N=C(OCCC=3N=CC=CC=3)N=C(C=2)N2CCOCC2)=C1 GAJWNIKZLYZYSY-OKUPSQOASA-N 0.000 claims 2
- 229960005343 ondansetron Drugs 0.000 claims 2
- 229960002131 palonosetron Drugs 0.000 claims 2
- CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 claims 2
- 229960002508 pindolol Drugs 0.000 claims 2
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 2
- 229960001534 risperidone Drugs 0.000 claims 2
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical group N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 2
- 229960000311 ritonavir Drugs 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- -1 rituximab Chemical compound 0.000 claims 2
- 230000019491 signal transduction Effects 0.000 claims 2
- 102100038028 1-phosphatidylinositol 3-phosphate 5-kinase Human genes 0.000 claims 1
- 101710145421 1-phosphatidylinositol 3-phosphate 5-kinase Proteins 0.000 claims 1
- 206010073360 Appendix cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000002471 Penile Neoplasms Diseases 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 102000004243 Tubulin Human genes 0.000 claims 1
- 108090000704 Tubulin Proteins 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 229940009456 adriamycin Drugs 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 208000021780 appendiceal neoplasm Diseases 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 239000000138 intercalating agent Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims 1
- 201000011519 neuroendocrine tumor Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000010916 pituitary tumor Diseases 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 208000013076 thyroid tumor Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021084241A JP2021121611A (ja) | 2015-07-20 | 2021-05-19 | アピリモドを用いる癌の処置方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562194367P | 2015-07-20 | 2015-07-20 | |
| US62/194,367 | 2015-07-20 | ||
| PCT/US2016/042905 WO2017015262A1 (en) | 2015-07-20 | 2016-07-19 | Methods for treating cancer using apilimod |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021084241A Division JP2021121611A (ja) | 2015-07-20 | 2021-05-19 | アピリモドを用いる癌の処置方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018525358A JP2018525358A (ja) | 2018-09-06 |
| JP2018525358A5 true JP2018525358A5 (enExample) | 2019-08-29 |
Family
ID=56551023
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018502669A Pending JP2018525358A (ja) | 2015-07-20 | 2016-07-19 | アピリモドを用いる癌の処置方法 |
| JP2021084241A Withdrawn JP2021121611A (ja) | 2015-07-20 | 2021-05-19 | アピリモドを用いる癌の処置方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021084241A Withdrawn JP2021121611A (ja) | 2015-07-20 | 2021-05-19 | アピリモドを用いる癌の処置方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10350213B2 (enExample) |
| EP (1) | EP3325014B1 (enExample) |
| JP (2) | JP2018525358A (enExample) |
| KR (1) | KR20180030630A (enExample) |
| CN (1) | CN108025076A (enExample) |
| AU (1) | AU2016297555B2 (enExample) |
| BR (1) | BR112018000776A2 (enExample) |
| CA (1) | CA2991779A1 (enExample) |
| IL (1) | IL256836B (enExample) |
| MX (1) | MX2018000715A (enExample) |
| RU (1) | RU2738934C2 (enExample) |
| TW (1) | TWI746449B (enExample) |
| WO (1) | WO2017015262A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2016134406A (ru) | 2014-01-24 | 2018-03-01 | Лэм Терапьютикс, Инк. | Композиции апилимода и способы их применения |
| CN107206090A (zh) * | 2014-11-07 | 2017-09-26 | 拉姆医疗公司 | 阿匹莫德在结肠直肠癌治疗中的用途 |
| PL3215158T3 (pl) | 2014-11-07 | 2019-11-29 | Ai Therapeutics Inc | Apilimod do zastosowania do leczenia raka nerki |
| TWI746449B (zh) | 2015-07-20 | 2021-11-21 | 美商Ａｉ治療公司 | 使用阿吡莫德治療癌症之方法 |
| WO2017127661A1 (en) * | 2016-01-21 | 2017-07-27 | Lam Therapeutics, Inc. | Biomarkers for treating cancer with apilimod |
| EP3678648B1 (en) | 2017-09-08 | 2023-07-26 | Insignis Therapeutics, Inc. | Methods of using dipivefrin |
| US10751345B2 (en) | 2018-02-21 | 2020-08-25 | AI Therapeutics, Inc. | Combination therapy with apilimod and glutamatergic agents |
| KR20220140515A (ko) | 2020-01-13 | 2022-10-18 | 버지 애널리틱스, 인크. | 치환된 피라졸로-피리미딘 및 그의 용도 |
| WO2022094058A1 (en) * | 2020-10-28 | 2022-05-05 | The Regents Of The University Of Michigan | Methods for preventing or treating conditions related to pikfyve activity |
| WO2022261499A1 (en) * | 2021-06-11 | 2022-12-15 | AI Therapeutics, Inc. | Stabilized apilimod compositions and uses thereof |
| EP4444310A4 (en) * | 2021-12-10 | 2025-11-19 | Verastem Inc | POLYTHERAPY FOR THE TREATMENT OF ABNORMAL CELL GROWTH |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
| WO2025175564A1 (en) * | 2024-02-23 | 2025-08-28 | The Regents Of The University Of Michigan | Method for treating autophagy dependent cancer with a pikfyve degrader |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6693097B2 (en) | 2001-11-30 | 2004-02-17 | Synta Pharmaceuticals Corp. | Pyrimidine compounds |
| CU23475A1 (es) * | 2004-07-08 | 2009-12-17 | Ct Ingenieria Genetica Biotech | Composición farmacéutica conteniendo fragmentos polipeptídicos de serralisinas |
| TW200630363A (en) | 2004-11-10 | 2006-09-01 | Synta Pharmaceuticals Corp | Process for preparing trisubstituted pyrimidine compounds |
| US7863270B2 (en) | 2005-05-13 | 2011-01-04 | Synta Pharmaceuticals Corp. | IL-12 modulatory compounds |
| WO2006128129A2 (en) * | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| RU2350338C2 (ru) * | 2007-05-14 | 2009-03-27 | ФГУ Ростовский научно-исследовательский онкологический институт Росздрава | Способ лечения поверхностного рака мочевого пузыря |
| RU2421217C2 (ru) * | 2009-09-03 | 2011-06-20 | Учреждение Российской академии медицинских наук Гематологический научный центр РАМН (ГНЦ РАМН) | Способ дифференцированного лечения диффузных в-крупноклеточных лимфосарком лимфоидных органов взрослых |
| HK1199261A1 (en) * | 2011-09-26 | 2015-06-26 | Galera Labs, Llc | Methods for treatment of diseases |
| IL291945B2 (en) * | 2012-11-01 | 2025-11-01 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
| WO2014159745A1 (en) * | 2013-03-14 | 2014-10-02 | Pharmacyclics, Inc. | Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors |
| CA2899577C (en) * | 2013-04-03 | 2023-10-17 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| MX2016007885A (es) * | 2013-12-17 | 2017-01-11 | Genentech Inc | Metodos de tratamiento de cancer usando antagonistas de union del eje de pd-1 y un anticuerpo anti-cd20. |
| JP7060324B2 (ja) * | 2013-12-20 | 2022-04-26 | ザ・ブロード・インスティテュート・インコーポレイテッド | ネオ抗原ワクチンによる併用療法 |
| RU2016134406A (ru) * | 2014-01-24 | 2018-03-01 | Лэм Терапьютикс, Инк. | Композиции апилимода и способы их применения |
| TWI746449B (zh) | 2015-07-20 | 2021-11-21 | 美商Ａｉ治療公司 | 使用阿吡莫德治療癌症之方法 |
-
2016
- 2016-07-15 TW TW105122406A patent/TWI746449B/zh not_active IP Right Cessation
- 2016-07-19 CN CN201680054093.3A patent/CN108025076A/zh active Pending
- 2016-07-19 CA CA2991779A patent/CA2991779A1/en not_active Abandoned
- 2016-07-19 WO PCT/US2016/042905 patent/WO2017015262A1/en not_active Ceased
- 2016-07-19 MX MX2018000715A patent/MX2018000715A/es unknown
- 2016-07-19 AU AU2016297555A patent/AU2016297555B2/en not_active Ceased
- 2016-07-19 JP JP2018502669A patent/JP2018525358A/ja active Pending
- 2016-07-19 KR KR1020187004110A patent/KR20180030630A/ko not_active Ceased
- 2016-07-19 EP EP16744650.9A patent/EP3325014B1/en active Active
- 2016-07-19 RU RU2018105923A patent/RU2738934C2/ru active
- 2016-07-19 US US15/213,829 patent/US10350213B2/en not_active Expired - Fee Related
- 2016-07-19 BR BR112018000776A patent/BR112018000776A2/pt not_active Application Discontinuation
-
2018
- 2018-01-10 IL IL256836A patent/IL256836B/en active IP Right Grant
-
2021
- 2021-05-19 JP JP2021084241A patent/JP2021121611A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018525358A5 (enExample) | ||
| RU2018105923A (ru) | Способы лечения рака с использованием апилимода | |
| Mehmood | Review of Cisplatin and oxaliplatin in current immunogenic and monoclonal antibody treatments. | |
| JP2017535601A5 (enExample) | ||
| JP6757959B2 (ja) | 抗がん剤 | |
| JP2012523435A5 (enExample) | ||
| JP2019501204A5 (enExample) | ||
| RU2017119065A (ru) | Апилимод для применения в лечении рака почек | |
| RU2011142806A (ru) | Комбинации пентамидина для лечения рака | |
| RU2018135317A (ru) | Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии | |
| RU2017134148A (ru) | Комбинация тасквинимода или его фармацевтически приемлемой соли и ингибитора pd-1 и/или pd-l1 для применения в качестве лекарственного средства | |
| JP2018521135A5 (enExample) | ||
| Zanjirband et al. | Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer | |
| RU2018105985A (ru) | Новый подход к лечению рака с применением иммуномодуляции | |
| RU2017104909A (ru) | Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства | |
| IL278423B2 (en) | Pd-1 / pd-l1 inhibitors for the treatment of cancer | |
| JP2017507990A5 (enExample) | ||
| JP7491220B2 (ja) | 免疫チェックポイント阻害薬およびｆｏｌｆｉｒｉｎｏｘ療法との併用によるがん治療 | |
| JP2012082234A5 (enExample) | ||
| RU2009149451A (ru) | Лечение антителами против vegf | |
| JP2015512398A5 (enExample) | ||
| Mehmood et al. | Review of cisplatin and oxaliplatin in current immunogenic and monoclonal antibodies perspective | |
| JP2016503414A5 (enExample) | ||
| JP2013213055A5 (enExample) | ||
| JP2019533651A5 (enExample) |